(201105). Liraglutide for the treatment of type 2 diabetes. Health Technology Assessment15 (Suppl 1): 77–86. PMID21609656. DOI: 10.3310/hta15suppl1/09.
(201706). Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ357: j2499. PMID28596247. PMC5463186. DOI: 10.1136/bmj.j2499.
(201304). Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Internal Medicine173 (7): 534–539. PMID23440284. DOI: 10.1001/jamainternmed.2013.2720.
(201402). Pancreatic safety of incretin-based drugs--FDA and EMA assessment. The New England Journal of Medicine370 (9): 794–797. PMID24571751. DOI: 10.1056/NEJMp1314078.
(en) (200611). Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY?. Physiology & Behavior89 (4): 460–464. PMID16828127. DOI: 10.1016/j.physbeh.2006.05.048.
(201105). Liraglutide for the treatment of type 2 diabetes. Health Technology Assessment15 (Suppl 1): 77–86. PMID21609656. DOI: 10.3310/hta15suppl1/09.
(201706). Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ357: j2499. PMID28596247. PMC5463186. DOI: 10.1136/bmj.j2499.
(201304). Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Internal Medicine173 (7): 534–539. PMID23440284. DOI: 10.1001/jamainternmed.2013.2720.
(201402). Pancreatic safety of incretin-based drugs--FDA and EMA assessment. The New England Journal of Medicine370 (9): 794–797. PMID24571751. DOI: 10.1056/NEJMp1314078.
(en) (200611). Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY?. Physiology & Behavior89 (4): 460–464. PMID16828127. DOI: 10.1016/j.physbeh.2006.05.048.